Quantcast Acelity - PROMOGRAN PRISMA™ Matrix


The information on this page is intended for healthcare professionals. Patient-specific information is available in the “Patients” section of this site. Patients should consult a healthcare professional regarding specific medical conditions and treatments.


A Clinically Proven Combination

PROMOGRAN PRISMA™ Matrix is comprised of a sterile, freeze dried composite of 44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC. Silver-ORC contains 25 % w/w ionically bound silver, a well-known antimicrobial agent.
Optimum wound environment
PROMOGRAN PRISMA™ Matrix maintains a physiologically moist microenvironment at the wound surface. This environment is conducive to granulation tissue formation, epithelization and optimal wound healing. Ionically-bound silver is an antimicrobial agent.
Clinically Proven
The efficacy of PROMOGRAN PRISMA™ Matrix is supported by a body of clinical evidence, including 1 published RCT1.

How it Works

  • About
  • Materials For Download


Maintains an optimum wound-healing environment

In the presence of exudate, PROMOGRAN PRISMA™ Matrix transforms into a soft, conformable, biodegradable gel, allowing contact with all areas of the wound.
PROMOGRAN PRISMA™ Matrix maintains a physiologically moist microenvironment at the wound surface. This environment is conducive to granulation tissue formation, epithelialization and optimal wound healing.
  • Optimum wound environment
  • Clinically proven
PROMOGRAN PRISMA™ Matrix How Does It Work
PROMOGRAN PRISMA™ Matrix How Does It Work

Indications & Applications

Indications & Applications

Indications for Use

PROMOGRAN PRISMA™ Matrix is intended for the management of exuding wounds.
Under the supervision of a health care professional, PROMOGRAN PRISMA™ Matrix
may be used for the management of:
  • Diabetic ulcers
  • Venous ulcers
  • Pressure ulcers
  • Ulcers caused by mixed vascular etiologies
  • Full-thickness and partial thickness wounds
  • Donor sites and other bleeding surface wounds
  • Abrasions
  • Traumatic wounds healing by secondary intention
  • Dehisced surgical wounds
Please refer to the full instructions for use in the packaging insert

Usage Videos

Evidence & Outcomes

The efficacy of PROMOGRAN PRISMA Matrix is supported by clinical evidence, including a published RCT.

Clinical Evidence

Additional summary of evidence and outcomes.

Evidence & Outcomes

Supporting Publications

Title Study Type Date Authors
Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair and Regeneration. 2002 Jan 1;10(1):16-25
Case Study
Cullen B, Smith R, Mcculloch E, Silcock D, Morrison L.
Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries. Journal of Wound Care. 2002 Feb 1;11(2):70-74
Economic Study
Ghatnekar O, Willis M, Persson U.
Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment. Wound Repair and Regeneration. 2013 Mar-Apr;21(2):216-25. Epub 2013 Feb 25.
Case Study
Gottrup F, Cullen BM, Karlsmark T, Bischoff-Mikkelsen M, Nisbet L, Gibson MC.
Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and Its Complications. 2007 Nov 1;21(6):387-391
Prospective Cohort Study
Kakagia DD, Kazakos KJ, Xarchas KC, et al.
Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. Journal of Diabetes and Its Complications. 2006 Sep-Oct;20(5):329-35
Case Study
Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H.
A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Archives of Surgery. 2002 Jul 1;137(7):822-827
Randomized Control Trial
Veves A, Sheehan P, Pham HT.
Wound conditioning of a deep tissue defect including exposed bone after tumour excision using PROMOGRAN* Matrix, a protease-modulating matrix. International Wound Journal. 2005 Sep;2(3):253-7.
Case Study
Tausche AK, Sebastian G.
The healing properties of Promogran in venous leg ulcers. Journal of Wound Care. 2002 Oct 1;11(9):335-341
Case Study
Vin F, Teot L, Meaume S.
Some effects of a topical collagen-based matrix on the microcirculation and wound healing in patients with chronic venous leg ulcers: preliminary observations. International Journal of Lower Extremity Wounds. 2005 Dec 1;4(4):214-224
Prospective Study
Wollina U, Schmidt WD, Kronert C, Nelskamp C, Scheibe A, Fassler D.
Use of a protease-modulating matrix in the treatment of pressure sores. Chirurgia Italiana. 2005 Jul 1;57(4):465-468
Prospective Cohort Study
Nisi G et al.

Ordering Information

Product Codes

Product Item Code Eaches/Carton/Box/HCPCS Code
4.34 sq. in. Hexagon
Box of 40 (4 Cartons of 10)
HCPCS Code A6021
19.1 sq. in. Hexagon
Box of 40 (4 Cartons of 10)
HCPCS Code A6022
Want to learn more? Please call +1 800-275-4524 or click here.

Footer Navigation